

Contents

1	Introduction	1
1.1	Developing a New Medicine	1
1.2	Key Risks at the Candidate Selection Stage	4
1.3	Attrition in the Pharmaceutical Industry	5
1.4	Evolution of the Pharma R&D Over the Last Two Decades	6
1.5	Pharma R&D Productivity in Decline	8
1.6	Cost of Pharma R&D and Cost Up to Candidate Selection	9
1.7	Increased Risks in Developing a Topical Drug	10
1.8	Increased Opportunities to Develop a Topical Drug	12
	References	12
2	Choosing Topical Drug Candidate: Historical Overview	15
2.1	The Pragmatic Topical Drug Development Approach: An Existing Oral/Systemic Drug is Further Developed as a Topical	15
2.1.1	Local Anaesthetics (<1900)	15
2.1.2	Corticosteroids (1952)	16
2.1.3	Retinoids (1962)	16
2.1.4	Antifungals (1967)	17
2.1.5	NSAIDS (1971)	17
2.1.6	Antivirals (1983)	18
2.1.7	Vitamin D3 Derivatives (Late 1980s)	18
2.1.8	Immunosuppressors (1992)	19
2.1.9	Summary	19
2.2	Moving towards Improved Topical Drug Candidate Selection Processes: Use of In Vivo Models	20
2.2.1	The Particular Case of Corticosteroids: Use of Human Models (Early 1960s)	20
2.2.2	Topical Rodent Models (1960s)	21

2.2.3	Combined Use of Topical Models and Systemic Rodent Models (1980s)	22
2.2.4	Use of Topical Pig Models (1990s).....	22
2.3	Historical Topical Drug Candidate Selection Summary	24
	References.....	25
3	Key Factors Affecting the Efficacy of a Topical Drug Candidate: Learnings from Past Topical Drug Development	29
3.1	Skin Barrier Condition vs. “Easiness” of Topical Drug Development.....	29
3.1.1	Skin and Its Barrier	29
3.1.2	Skin Disease, Target Site in Skin and Skin Barrier Properties	30
3.1.3	Success Rate of First in Class Topical Drugs.....	31
3.1.4	Summary of Impact of Skin Disease, Its Target Site, Its Barrier and Success Rate of Topical Drug Development.....	32
3.2	Drug Potency and Clinical Efficacy	34
	References.....	35
4	Topical Versus Oral/Systemic Drug Discovery	39
4.1	Drug Discovery Evolution	39
4.2	Oral/Systemic Drug Discovery	40
4.3	Topical Drug Discovery	41
4.4	Two Key Differences in Discharging Risk in Between the Oral/Systemic and Topical Drug Discovery Processes.....	43
4.4.1	Defining Target Tissue (Skin) Concentration	43
4.4.2	Checking that Pharmacokinetic Parameters Are Appropriate.....	44
4.5	Consequences for Preclinical Stage: “Maximising Percutaneous Flux”	46
4.6	Learnings from the Oral Drug Development Process.....	47
	References.....	47
5	Assessing Drug Concentration in Skin: Direct and Indirect Methods.....	49
5.1	Direct Methods.....	49
5.1.1	Tape Stripping (Vitro/Vivo).....	49
5.1.2	Skin Biopsy	51
5.1.3	<i>In Vitro</i> Percutaneous Studies: Skin Tissue Concentration	52
5.1.4	Suction Blister	53
5.1.5	Skin Surface Contamination Issue	54
5.2	Indirect Methods	58
5.2.1	Introduction	58
5.2.2	Plasma Collection.....	58

5.2.3	Microdialysis.....	59
5.2.4	<i>In Vitro</i> Percutaneous Studies: Percutaneous Flux	61
5.3	Potential Use of the Skin Pharmacokinetic Sampling Methods, Comparisons of Methods and Consequences	61
5.4	Using Percutaneous Flux or Plasma Concentration as Surrogate Measurement of Skin Concentration	63
	References.....	66
6	Assessing Topical Efficacy	69
6.1	Assessing Efficacy and Dose Prediction for a Systemic Target	69
6.2	Pharmacodynamic Models.....	70
6.2.1	Rodents.....	70
6.2.2	Minipigs	71
6.2.3	Human Microplaque Assay	72
6.2.4	<i>In Vitro</i> Pharmacodynamic Models.....	73
6.2.5	“ <i>In Silico</i> ” PK/PD Approaches	74
6.3	Conclusion	82
	References.....	83
7	Assessing Therapeutic Index.....	87
7.1	Introduction.....	87
7.2	A “Crude” Approach: Comparing the Mass of Target Tissue with Total Body Mass.....	88
7.3	Calculated Approach.....	89
7.4	Comparative Approach	91
	References.....	93
8	Topical Vehicle Selection: Myths and Reality.....	95
8.1	Introduction.....	95
8.2	Skin Penetration Enhancement	96
8.3	Retention in Skin.....	97
8.4	For Each Compound, A Specific Formulation: A Must?	99
8.5	Vehicle Aesthetics	101
8.6	Drug Formulated as a Dispersion or as a Solution?.....	105
8.7	Conclusion	105
	References.....	106
9	Dermal Drug Development Strategies.....	109
9.1	Option#1: Clinical Molecule Repurposing—Developed Drug for a Non Systemic Indication on a New Target Class	109
9.2	Option#2: Full Lead Optimization—New Drug from a New Mechanism of Action for a Topical Application	111
9.3	Option#3: “Me Better”—Improved Drug for a Known Topical Target Class.....	111

9.4	Option#4: Chemical Series Repurposing—Advanced Lead Optimized Chemicals Series Screened Against for a Topical Indication.....	112
	Reference	113
10	Topical Drug Candidate Selection Criteria and Cascade.....	115
10.1	General Principles: Discharging Risk.....	115
10.2	Medicinal Chemistry and Chemical Space.....	116
10.3	Potency.....	117
10.4	Percutaneous Flux.....	118
10.5	Pharmacological Kinetics Response.....	122
10.6	Preclinical Proof of Concept.....	123
10.7	Solution Stability—Water Stability	123
10.8	UV Absorption.....	124
10.9	Local Irritation	125
10.10	Systemic Effect (Clearance & Protein Binding).....	125
10.11	Other Criteria Not that Important for a Topical Candidate.....	125
	10.11.1 Skin Metabolism.....	125
	10.11.2 CYP 450 Inhibition/Induction and Drug Drug Interaction.....	126
10.12	Comparison of the Criteria Used to Select an Oral/Systemic Candidate and a Topical One	126
10.13	Example of Candidate Selection Cascade When Repurposing a Whole Chemical Series.....	128
	References.....	130
11	Selecting Dermal Drug Candidate: Some Useful Quotations and “Rules”.....	133
11.1	“Manage Every One’s Expectation on Chance of Success... Even If Skin Is Thin and the Target Site Less than 1 mm Down, Delivering through the Topical Route Is Challenging”.....	133
11.2	“Don’t Believe the Molecule You Have Developed for a Systemic Route Is the Best One You Have from Your Lead Optimisation Effort... Look for a Better One”	134
11.3	“Don’t Be Scared of the Systemic Toxicological Findings Associated with the Target... It Is Most of the Time Not of Concern and Manageable”	134
11.4	“Expect a Substantial Toxcological Package to Develop a Topical NCE and a Long Development Time”	134
11.5	“Prefer Minipig to Rodent for the Toxicological Package If You Don’t Want to Stop Your Asset for a Wrong Reason: Exacerbated Local Tox that Would Not Translate in Human”.....	135

11.6	“For an In Vitro Skin Permeation, If Substantial Concentration Appears to Have Been Achieved in Skin While Nothing Is Found in the Receiving Fluid, this Is Bad News Not Good News”	135
11.7	“Don’t Believe in Compound Retention in the Viable Epidermis or Dermis”	135
11.8	“Don’t Expect Miracles from the Formulation in Terms of Drug Delivery”	136
11.9	“Don’t Go with Fancy “Gunky” Vehicle... Think of the Patients and the Aesthetics Required for a Topical”	136
11.10	“Don’t Expect a Large Molecule to Cross the Stratum Corneum”	136
11.11	“If Possible, Chose a Candidate Molecule with a Long Skin Crossing Time”	137
11.12	“Put a Relevant Screening Cascade: Discharge Early the Key Risks of a Topical Drug... Delay the Other Data”	137
11.13	“Deeper the Target the More Difficult to Engage the Target”	137
11.14	“Think ‘Ligand Efficiency’ as a Way to Improve the ‘Compound Topical Power’ ”	138
12	Conclusions and Perspectives	139
	Reference	143
Index		145

Dermal Drug Selection and Development

An Industrial Perspective

Trottet, L.; Maibach, H.I.

2017, XVI, 148 p. 53 illus., 35 illus. in color., Hardcover

ISBN: 978-3-319-59503-0